XIAMEN, China--(BUSINESS WIRE)--Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx ® ROS1 test successfully ...
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer (NSCLC) (NCT02299141). This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This ...
An ultra-deep next generation sequencing method for cfDNA detection in NSCLC patients. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results